Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Real-World Evidence Could Help Relax Clinical Trial Enrollment Criteria

Executive Summary

FOCR study suggests overall survival for PD-1s seen in real-world datasets is similar to results from clinical trials.

You may also be interested in...



AstraZeneca Tagrisso, Pfizer Xalkori Stand Out Among US FDA’s Single-Arm Oncology Approvals, JAMA Suggests

Only two US approvals based on single-arm trials met the European Society for Medical Oncology’s threshold for substantial clinical benefit, according to an analysis of cancer drugs approved over a decade.

Real-World Evidence Challenges: Death Among Toughest Data Points To Measure

Death typically is not included in electronic health records, and sources are disparate; Difficulties with endpoint expose potential limitation to real-world evidence use.

US FDA Wants More Examples Of Real-World Data Use

CDER Director Woodcock says for regulatory purposes, using real-world data likely will remain a case-by-case decision.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS123384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel